Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Wellbeing Digital Sciences Inc
(OP:
KONEF
)
N/A
UNCHANGED
Last Price
Updated: 3:57 PM EST, Mar 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Wellbeing Digital Sciences Inc
< Previous
1
2
3
Next >
World's Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees
June 26, 2023
The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gathered over 12,000 people from the entire psy
Via
Benzinga
Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference
June 19, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group
June 16, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference
May 25, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response
May 03, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
April 18, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval
April 11, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Announces Cease Trade Order
April 06, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Provides Bi-Weekly Default Status Report
March 16, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
March 16, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
March 13, 2023
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial
Via
Benzinga
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
March 13, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License
March 09, 2023
A Contract Research Organization (CRO) and a wholly-owned subsidiary of Wellbeing Digital Sciences Inc.
Via
Benzinga
Wellbeing Digital to Participate in The Global Biomedical Design Conference
March 09, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
March 08, 2023
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established...
Via
Benzinga
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout
March 08, 2023
From
WELLBEING DIGITAL SCIENCES
Via
Business Wire
Wellbeing Provides Bi-Weekly Default Status Report
March 02, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event
March 01, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Via
Benzinga
Wellbeing Provides Bi-Weekly Default Status Report
February 16, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
February 15, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
February 14, 2023
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a...
Via
Benzinga
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
February 14, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order
February 01, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers
January 30, 2023
In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council.
Via
Benzinga
Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar
January 25, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Digital Announces Change of Auditor
January 18, 2023
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
December 27, 2022
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a...
Via
Benzinga
Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
December 22, 2022
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada
December 08, 2022
From
Wellbeing Digital Sciences Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.